🔎 Trials Near Me

Home › Neuroblastoma

Neuroblastoma clinical trials recruiting in the U.S.

47 studies for Neuroblastoma are recruiting participants at sites across the United States.

Neuroblastoma is a cancer in nerve tissue in the adrenal gland, neck, chest, or spinal cord. It often affects young children. Read about treatments.

Cities with the most studies

By state

Recently updated studies

Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies

RecruitingObservational studyHealthy volunteers welcome
4 Weeks · All sexes · Updated Sep 28, 2026 · NCT01109394

Prospective Comprehensive Molecular Analysis of Endocrine Neoplasms

RecruitingObservational study
Ages 4 and older · All sexes · Updated Sep 22, 2026 · NCT01005654

Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)

RecruitingPhase 1/2
6 Months – 25 Years · All sexes · Updated Sep 17, 2026 · NCT06395103

Biomarkers of Resiliency In Childhood Cancer Surgery

RecruitingObservational study
Ages 3 to 25 · All sexes · Updated Sep 14, 2026 · NCT06674811

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy

RecruitingPhase 2
Up to age 22 · All sexes · Updated Sep 4, 2026 · NCT02559778

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

RecruitingPhase 1/2
Up to age 30 · All sexes · Updated Sep 3, 2026 · NCT06541262

B7-H3.CD28Z.CART in Solid Tumors

RecruitingPhase 1
9 Months – 30 Years · All sexes · Updated Sep 3, 2026 · NCT07358260

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

RecruitingPhase 1/2
Up to age 26 · All sexes · Updated Sep 3, 2026 · NCT06465199

Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

RecruitingPhase 2
Ages 1 to 21 · All sexes · Updated Sep 3, 2026 · NCT06540963

International Congenital Central Hypoventilation Syndrome (CCHS) Registry and CCHS SHARE

RecruitingObservational study
All ages · All sexes · Updated Sep 3, 2026 · NCT03088020

N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

RecruitingPhase 2
18 Months – 19 Years · All sexes · Updated Aug 28, 2026 · NCT06528496

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

RecruitingPhase 1/2
12 Months – 30 Years · All sexes · Updated Aug 25, 2026 · NCT04851119

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

RecruitingPhase 3
365 Days – 30 Years · All sexes · Updated Aug 25, 2026 · NCT03126916

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

RecruitingPhase 2
Ages 1 to 39 · All sexes · Updated Aug 24, 2026 · NCT07635056

Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

RecruitingPhase 1
Ages 1 to 23 · All sexes · Updated Aug 13, 2026 · NCT07172958

Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

RecruitingPhase 2
12 Months – 21 Years · All sexes · Updated Aug 12, 2026 · NCT05489887

A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma

RecruitingPhase 2Healthy volunteers welcome
All ages · All sexes · Updated Aug 11, 2026 · NCT04936529

SPEARHEAD-3 Pediatric Study

RecruitingPhase 1/2
Ages 2 to 21 · All sexes · Updated Aug 11, 2026 · NCT05642455

A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma

RecruitingPhase 2
All ages · All sexes · Updated Jul 28, 2026 · NCT06057948

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

RecruitingPhase 1/2
Ages 1 to 30 · All sexes · Updated Jul 22, 2026 · NCT06721689

NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

RecruitingPhase 1
Ages 1 to 24 · All sexes · Updated Jul 21, 2026 · NCT07211737

NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

RecruitingPhase 2
Ages 1 to 31 · All sexes · Updated Jul 20, 2026 · NCT06450041

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.